Business Context and Reporting Period
This Form 8-K Current Report was filed by Prelude Therapeutics Inc. on February 3, 2025. The filing addresses corporate governance changes, specifically the transition of an interim executive to a permanent role.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Bryant D. Lim as the permanent Chief Financial Officer (CFO), effective February 3, 2025. Mr. Lim previously served as interim CFO, Chief Legal Officer, and Corporate Secretary. He will continue to hold the latter two titles alongside his new permanent CFO role.
Management Commentary and Compensation Details
In connection with the permanent appointment, the Company entered into an Amended Executive Employment Agreement with Mr. Lim. Key terms include:
- Base Salary: $483,000 annually.
- Annual Bonus: Eligibility for a discretionary bonus of up to 40% of the Base Salary, based on objectives set by the Board.
- Equity Grant: An option to purchase 200,000 shares of common stock. Vesting occurs as 25% on the first anniversary of the grant date, with the remaining 75% vesting monthly thereafter (1/48th per month), contingent on continued service.
- Severance Provisions:
- Termination without Cause (unrelated to Change of Control): 9 months of Base Salary plus COBRA premiums.
- Termination without Cause or for Good Reason (related to Change of Control): 12 months of Base Salary plus COBRA premiums.
The full agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 200,000 stock options once the full agreement is filed in the 2024 Form 10-K.
- Review the specific definitions of "Cause," "Good Reason," and "Change of Control" in the employment agreement to understand severance triggers.
- Monitor future filings for any changes to the Board's objectives regarding the discretionary bonus component.